Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This purpose of this study is to evaluate the role of gemcitabine and docetaxel, a well
tolerated chemotherapy regimen in the treatment of advanced non-small cell lung cancer
(NSCLC), in combination with a novel agent cetuximab.